Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)

Jiyun Lee, MD; Aaron C. Tan, BSc, M.B.B.S., PhD, FRACP; Siqin Zhou, MSc Statistics; Shinkyo Yoon, MD, PhD; Siyang Liu, MD, PhD; Ken Masuda, MD; Hidetoshi Hayashi, MD, PhD; Ullas Batra, MD, DM; Dong-Wan Kim, MD, PhD; Yasushi Goto, MD, PhD; Sze Huey Tan, PhD; Yi-Long Wu, MD; Dae Ho Lee, MD, PhD; Daniel S.W. Tan, BSc, M.B.B.S., MRCP, PhD; Myung-Ju Ahn, MD, PhD

JTO Clinical and Research Reports (Jan 2022)

Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)

Jiyun Lee, MD,
Aaron C. Tan, BSc, M.B.B.S., PhD, FRACP,
Siqin Zhou, MSc Statistics,
Shinkyo Yoon, MD, PhD,
Siyang Liu, MD, PhD,
Ken Masuda, MD,
Hidetoshi Hayashi, MD, PhD,
Ullas Batra, MD, DM,
Dong-Wan Kim, MD, PhD,
Yasushi Goto, MD, PhD,
Sze Huey Tan, PhD,
Yi-Long Wu, MD,
Dae Ho Lee, MD, PhD,
Daniel S.W. Tan, BSc, M.B.B.S., MRCP, PhD,
Myung-Ju Ahn, MD, PhD

Affiliations

Jiyun Lee, MD: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Aaron C. Tan, BSc, M.B.B.S., PhD, FRACP: Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
Siqin Zhou, MSc Statistics: Biostatistics and Epidemiology Unit, Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore
Shinkyo Yoon, MD, PhD: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Siyang Liu, MD, PhD: Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, People’s Republic of China
Ken Masuda, MD: Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
Hidetoshi Hayashi, MD, PhD: Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
Ullas Batra, MD, DM: Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
Dong-Wan Kim, MD, PhD: Department of Internal Medicine, Clinical Trials Center, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Yasushi Goto, MD, PhD: Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
Sze Huey Tan, PhD: Biostatistics and Epidemiology Unit, Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore; Biostatistics and Quantitative Epidemiology, Singapore Health Services, Singapore, Singapore; Oncology ACP, Duke-NUS Graduate Medical School, Singapore, Singapore
Yi-Long Wu, MD: Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, People’s Republic of China
Dae Ho Lee, MD, PhD: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Daniel S.W. Tan, BSc, M.B.B.S., MRCP, PhD: Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore; Corresponding author. Address for correspondence: Daniel S. W. Tan, BSc, M.B.B.S., MRCP, PhD, Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore 169610, Singapore.
Myung-Ju Ahn, MD, PhD: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Journal volume & issue: Vol. 3, no. 1
p. 100261

Abstract

Read online

Introduction: Whereas interpatient heterogeneity in clinical characteristics and treatment outcomes of NSCLC harboring a KRAS mutation is recognized, the characterization of these patients in Asia has been limited. Methods: A multicenter, retrospective cohort study was conducted in eight academic centers across Asia. Patients diagnosed with advanced NSCLC harboring a KRAS mutation and who had received at least one line of anticancer therapy between January 2014 and December 2018 were included. Modified time to next treatment (TTNT) was adopted as a proxy for progression-free survival. Results: A total of 216 patients were analyzed. The median age at diagnosis of advanced NSCLC was 63.3 years, 70.8% were men and 89.8% had adenocarcinoma. KRAS G12D was the most common subtype (25.5%), followed by G12C (24.5%), and G12V (19.4%) The proportion of current or former smokers was 65.7% in the overall population, with 86.8% in G12C and 58.9% in non-G12C subgroups. For all treatments combined for the total population, the first-line duration of therapy, modified TTNT, and TTNT were 4.5 (95% confidence interval: 3.4–5.9), 6.2 (4.9–8.8), and 9.5 (7.1–11.4) months, respectively. The median overall survival for the total population was 10.3 (6.9–12.4) months and was prolonged in patients ever treated with immunotherapy (14.6 [8.6–19.1] versus 7.0 [5.9–10.6] mo, hazard ratio = 0.54, p < 0.001), with left truncation to account for the time of KRAS testing. Conclusions: Whereas treatment outcomes with conventional anticancer therapy are reasonable and immunotherapy looks promising, the unmet need remains high for patients with KRAS-mutated NSCLC in Asia, underscoring the need for novel therapeutic approaches.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords